Colorado-based startup Surefire Medical has raised $11 million to help market its microcatheter-based infusion system to deliver embolic agents to liver cancer. The Surefire Infusion System was cleared by the FDA in 2011, but it's in ongoing testing by external investigators to see how it compares to a standard end-hole microcatheter.
Bayer and Onyx Pharmaceuticals' Nexavar has seen a lot of success as a liver cancer treatment, but as an adjuvant therapy for liver cancer, it could be awhile--if ever. On Tuesday, the drug missed its target in a Phase III trial, failing to meet the study's main goal of improving recurrence-free survival.
Researchers in China published an article in the journal Biomedical Materials demonstrating the drug-delivery potential of new gold nanoshells for cancer that also use hyperthermic effects to bring toxic cancer drugs to tumors with fewer side effects.
Queensbury, NY-based Delcath plans to fire 20% of its U.S. workforce to conserve cash and concentrate resources in Europe, where the company has CE mark clearance for its drug-device combo.
Germany's federal healthcare reimbursement program approved Delcath Systems' Chemosat with a Value 4 status.
Celsion was the center of a considerable amount of market buzz over the last year as the small biotech pushed a late-stage cancer drug through a Phase III liver cancer study. Its stock price tripled as investors rode a swell of enthusiasm that Celsion could beat the tough odds that face any small-cap company trying to make it all the way through an oncology program.
Celsion ($CLSN) grabbed $5 million in a development deal with China's Zhejiang Hisun Pharmaceutical, which has shown interest in advancing Celsion's ThermoDox product in China, Hong Kong and Macau.
A team at The Scripps Research Institute has developed a compound that reduced and even reversed fatty liver disease in animals, and had the added bonus of reducing plasma cholesterol levels.
At the beginning of this month ArQule shares tanked on the news that it had decided to shelve a late-stage study of tivantinib for non-small cell lung cancer after investigators concluded that the data pointed to a clear failure. But today the biotech got a little of its lost luster back with the news that it had agreed with regulators on the design of a new Phase III, landing a special protocol assessment on its program for liver cancer.
The German biotech 4SC AG says its experimental drug resminostat extended overall survival among advanced liver cancer patients by 8 months in Phase II when combined with Bayer's Nexavar.